Short Interest in Assembly Biosciences, Inc. (NASDAQ:ASMB) Expands By 25.5%

Assembly Biosciences, Inc. (NASDAQ:ASMB) was the recipient of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 17,200 shares, an increase of 25.5% from the January 31st total of 13,700 shares. Based on an average trading volume of 33,700 shares, the short-interest ratio is presently 0.5 days. Currently, 0.5% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a report on Friday, December 27th.

Assembly Biosciences Price Performance

NASDAQ:ASMB opened at $11.43 on Friday. The business’s fifty day moving average price is $14.14 and its 200 day moving average price is $15.50. Assembly Biosciences has a 1-year low of $11.23 and a 1-year high of $19.93.

Insider Buying and Selling

In related news, Director Michael Houghton bought 3,202 shares of the business’s stock in a transaction dated Monday, December 30th. The shares were bought at an average cost of $15.61 per share, with a total value of $49,983.22. Following the completion of the transaction, the director now directly owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 5.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Assembly Biosciences

Large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in Assembly Biosciences by 5,137.3% during the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 3,442 shares in the last quarter. Palumbo Wealth Management LLC acquired a new position in shares of Assembly Biosciences in the fourth quarter worth $180,000. Marshall Wace LLP raised its holdings in shares of Assembly Biosciences by 16.5% during the fourth quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock worth $234,000 after acquiring an additional 2,098 shares in the last quarter. FMR LLC boosted its position in Assembly Biosciences by 29.7% during the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 3,635 shares during the last quarter. Finally, Man Group plc acquired a new position in Assembly Biosciences in the 4th quarter worth about $309,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.